A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
Conditions: Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies Intervention: Biological: CTX001 Sponsors: CRISPR Therapeutics; Vertex Pharmaceuticals Incorporated Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials